Genmab and Incyte are teaming up to develop an experimental colorectal cancer treatment. Early-stage oncology deal, so the read-through is pipeline optionality, not near-term revenue. $GMAB $INCY

What happened: Genmab ($GMAB) and Incyte ($INCY) announced a clinical trial collaboration to test Genmab's petosemtamab with Incyte's INCB161734 plus chemotherapy as a potential first-line treatment for advanced colorectal cancer with the KRAS G12D mutation. Key numbers: KRAS mutations occur in Why it matters: The collaboration gives both companies a chance to expand their cancer pipelines into a difficult-to-treat disease with substantial unmet needs, though effectiveness and safety remain unproven and the early-stage trial will determine whether the drugs warrant further development. Market: -1.0% today ($115.71), +14.1% YTD, 0.9x vol — as of 23:45 UTC

Genmab ($GMAB) and Incyte ($INCY) announced a clinical trial collaboration to test Genmab's petosemtamab with Incyte's INCB161734 plus chemotherapy as a potential first-line treatment for advanced colorectal cancer with the KRAS G12D mutation.

The collaboration gives both companies a chance to expand their cancer pipelines into a difficult-to-treat disease with substantial unmet needs, though effectiveness and safety remain unproven and the early-stage trial will determine whether the drugs warrant further development. Market: -1.0% today ($115.71), +14.1% YTD, 0.9x vol — as of 23:45 UTC